Clinical Trial Detail

NCT ID NCT02908906
Title A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications

Advanced Solid Tumor

Therapies

JNJ-63723283

Age Groups: adult senior

No variant requirements are available.